GVAX

Cell Genesys Announces Final Results from Phase 3 Program of GVAX Immunotherapy

HAYWARD, Calif.--(BUSINESS WIRE)--Feb. 27, 2009-- Cell Genesys, Inc. (NASDAQ:CEGE) announced today results from further analyses of VITAL-1, the Company’s recently terminated Phase 3 clinical trial which compared GVAX immunotherapy for prostate cancer to Taxotere® (docetaxel) chemotherapy plus prednisone and enrolled 626 advanced prostate cancer patients with asymptomatic castrate-resistant metastatic disease.